In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Comparing the Big 3, Semaglutide, Tirzepatide and Retatrutide : r Mounjaro Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Retatrutide vs Tirzepatide vs Semaglutide comparison Voy